Stay updated on Tisotumab Vedotin Continued Treatment in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Tisotumab Vedotin Continued Treatment in Solid Tumors Clinical Trial page.

Latest updates to the Tisotumab Vedotin Continued Treatment in Solid Tumors Clinical Trial page
- CheckyesterdayChange DetectedThe revision label in the page footer updated from v3.4.0 to v3.4.1; no changes to study details or eligibility information are visible.SummaryDifference0.1%

- Check8 days agoChange DetectedUI and labeling updates include showing the glossary toggle ('Show glossary'), capitalization/wording tweaks (e.g., 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data'), and a new revision tag 'Revision: v3.4.0'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedA new Revision: v3.3.4 notice was added and the Revision: v3.3.3 notice was removed from the page.SummaryDifference0.1%

- Check44 days agoChange DetectedAdded a Locations section with Florida as a site. Removed the old Florida Locations heading and the HHS Vulnerability Disclosure footer; page revision updated to v3.3.3.SummaryDifference0.2%

- Check72 days agoChange DetectedRevision: v3.3.2 added; Revision: v3.2.0 removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check80 days agoChange DetectedThe government funding lapse notice was removed from the page. Trial details, eligibility criteria, and study results remain unchanged.SummaryDifference0.4%

Stay in the know with updates to Tisotumab Vedotin Continued Treatment in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tisotumab Vedotin Continued Treatment in Solid Tumors Clinical Trial page.